Skip to main content
Signal8

Evogene Ltd. (EVGN)

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

Sector: Agricultural Chemicals

Industry: Biotechnology

Evogene Ltd. logo

Evogene Ltd.

NASDAQ:EVGNHealthcare
AH+8.76%$0.3699
Close$0.3401-13.17%
Mkt Cap$6.14M
EV-
Float13.65M
O/S18.05M
VOL254K sh
$ Vol$92K
RVOL0.47×
Inst Own2.3%
SI0.5%
Net Cash/Sh-
Dilution
Evogene Ltd. logoNASDAQ:EVGNAH$0.3699+8.76%
Short interest (FINRA)
0.5%
Oct 30 (18d)

Float 13.65M · Signal8 dilution snapshot · Sep 28, 2026

70.3K
Oct 30 (18d)prev 63.9K▲ 10.1%
2.33
Oct 30 (18d)prev 1.00▲ 133.0%
Borrow (IBKR)

The cost to borrow EVGN shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
50.3%
Nov 16 (1d)prev 41.8%▲ 8.5 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

896
Oct 30 (18d)prev 9▲ 9855.6%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver24 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 202670.3K sh
Oct 15, 202663.9K sh
Sep 30, 2026932.7K sh
Sep 15, 202656.8K sh
Aug 31, 202653.0K sh
Latest fails to deliver
DateShares failed
Oct 30, 2026896 sh
Oct 28, 20269 sh
Oct 27, 2026943 sh
Oct 26, 2026217 sh
Oct 23, 20263.1K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 16
Latest sessions
DateReported short
Nov 16, 202650.3%
Nov 13, 202641.8%
Nov 12, 202650.3%
Nov 11, 202622.7%
Nov 10, 202636.9%
89-session median 29.3%mean 30.3%range 1.1–90.3%

130 calendar days requested; 90 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for EVGN: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 70,324 EVGN shares were sold short (0.52% of a 13.65M-share float, 2.33 days to cover).